Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Medical Genetics

What Does an Amenable Mutation Mean in Fabry Disease?

At a Glance

An amenable mutation in Fabry disease means your body produces a misshapen but fixable alpha-Gal A enzyme. This specific genetic result indicates you may be eligible for an oral medication called chaperone therapy (migalastat), which corrects the enzyme's shape, rather than requiring lifelong IV infusions.

In this answer

4 sections

01

The Problem: Misshapen but Not Missing

02

How Chaperone Therapy Works

03

Why Some Mutations Are Not Amenable

04

What This Means for Your Health and Treatment

An amenable mutation is a specific type of genetic change that qualifies a person with Fabry disease for oral treatment rather than traditional intravenous (IV) infusions [1]. If your genetic report says your mutation is amenable, it means your body produces an alpha-galactosidase A (alpha-Gal A) enzyme that is misshapen but still retains the potential to work [2]. Because of this specific shape, you may be eligible for an oral medication called chaperone therapy (migalastat), which can fix the enzyme’s shape and help it function properly [3].

The Problem: Misshapen but Not Missing

In Fabry disease, a mutation in the GLA gene causes the body to produce either no alpha-Gal A enzyme or a faulty version of it. The job of this enzyme is to act as a cellular recycling worker, breaking down a fatty substance called GL-3 (or Gb3) in the cell’s recycling center (the lysosome).

When you have an amenable mutation, your body is still manufacturing the enzyme, but it is folded into the wrong shape [2][4]. The cell has a strict internal quality control system. When it detects a misshapen protein, it tags it as defective and destroys it before it can ever reach the lysosome [5][6]. Because the enzyme never makes it to the right place, fatty substances build up and cause the symptoms of Fabry disease [7].

How Chaperone Therapy Works

For decades, the standard treatment for Fabry disease has been Enzyme Replacement Therapy (ERT), which involves regular, lifelong IV infusions of a synthetic enzyme to replace what the body is missing [8][6].

Having an amenable mutation gives you another option: a pill taken every other day called migalastat (also known by the brand name Galafold) [1][3]. Migalastat is a pharmacological chaperone, meaning it acts like a microscopic scaffold. The drug binds directly to your own misshapen enzymes, stabilizing them and helping them fold into the correct shape [2][9]. This protective scaffold hides the enzyme from the cell’s quality control system, allowing it to travel safely to the lysosome [5]. Once it arrives in the highly acidic environment of the lysosome, the medication detaches, and your own enzyme can finally go to work breaking down the fatty buildup [4].

Why Some Mutations Are Not Amenable

Chaperone therapy only works if there is a partially functioning enzyme to rescue. It cannot create an enzyme from scratch. Therefore, mutations that result in no enzyme being produced at all—such as large missing chunks of DNA (called deletions)—are considered non-amenable [6]. Migalastat would have nothing to bind to in these cases.

You do not need to undergo a special, real-time science experiment on your own blood to find out if your mutation is amenable. Instead, scientists have already tested thousands of known GLA mutations in the laboratory to see how they respond to the drug [6][10]. Your doctor simply checks your genetic test results against this established database to see if your specific mutation is on the “amenable” list [11].

What This Means for Your Health and Treatment

For patients aged 16 and older who qualify, oral chaperone therapy is generally just as effective as traditional IV ERT at stabilizing key health markers [12][13]. Patients currently receiving IV infusions can safely switch to the pill if their mutation is amenable [14][15].

Clinical studies demonstrate that migalastat helps:

  • Maintain kidney function [2][16]
  • Reduce the thickening of heart walls (measured as left ventricular mass index) [17][18]
  • Lower the amount of fatty buildup (lyso-Gb3) in the blood [19]
  • Avoid the inconvenience and potential complications of lifelong intravenous infusions [20][3]

Taking the Medication: To ensure the body absorbs the drug properly, migalastat must be taken on an empty stomach. This typically requires fasting from food for at least two hours before and two hours after taking the dose [21].

Side Effects: Migalastat is generally well-tolerated and has a safety profile similar to ERT [22]. The most common side effects include headache, urinary tract infections, cold-like symptoms, and nausea [23][24].

However, everyone responds to medication differently. Your care team will still need to monitor your heart, kidneys, and bloodwork regularly to ensure the oral therapy is effectively controlling your disease [25][18].

Common questions in this guide

What is an amenable mutation in Fabry disease?
An amenable mutation means your body produces an alpha-galactosidase A enzyme that is misshapen but can still potentially function. This specific genetic result means you may be eligible for oral chaperone therapy instead of traditional IV infusions.
How does migalastat work for amenable mutations?
Migalastat acts like a microscopic scaffold that binds to your misshapen enzymes and helps them fold into the correct shape. This protects the enzyme from being destroyed by the cell's quality control system, allowing it to travel to the lysosome and break down fatty buildups.
Why are some Fabry disease mutations non-amenable?
Chaperone therapy requires a partially functioning enzyme to rescue. If your genetic mutation causes your body to produce no enzyme at all, the medication has nothing to bind to, making the mutation non-amenable to this oral treatment.
Can I switch from IV enzyme replacement therapy to the oral pill?
Yes, patients currently receiving intravenous enzyme replacement therapy can safely switch to oral chaperone therapy if their genetic test confirms they have an amenable mutation. Your care team will monitor your heart, kidneys, and bloodwork to ensure the transition is successful.
Are there special instructions for taking migalastat?
Yes, migalastat must be taken every other day on an empty stomach. You typically need to fast from food for at least two hours before and two hours after taking the medication to ensure your body absorbs the drug properly.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you provide me with the exact name and classification of my GLA mutation for my records?
  2. 2.Am I a good candidate to switch from IV enzyme replacement therapy to oral chaperone therapy?
  3. 3.What are the common side effects I should watch out for if I start taking migalastat?
  4. 4.How often will we monitor my kidney and heart function to ensure the oral medication is working effectively?
  5. 5.Are there any specific medications or supplements I should avoid taking alongside migalastat?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Female Carriers of Fabry Disease Have Severe Symptoms?How Is Enzyme Replacement Therapy Administered for Fabry?How Is Fabry Disease Inherited From a Father?How Is Fabry Disease Inherited From a Mother?How Often Should I Get a Cardiac MRI for Fabry Disease?How Do You Manage Heat Intolerance in Fabry Disease?How to Transition a Child With Fabry to Adult CareHow to Treat Fabry Disease Nerve Pain in Hands & FeetCan Your Body Stop Responding to Fabry Disease ERT?What Are the Common Misdiagnoses for Fabry Disease?Fabry Disease Prognosis: What Is the Life Expectancy?What is the Lyso-Gb3 Test for Fabry Disease?What Specialists Treat Fabry Disease? Care Team GuideWhy Do Women Need Genetic Testing for Fabry Disease?

References

References (25)
  1. 1

    Cardiac manifestations of Fabry disease.

    Dougherty S, Germain DP, Oudit GY, et al.

    NPJ cardiovascular health 2025; (2(1)).

    PMID: 41776073
  2. 2

    Migalastat: A Review in Fabry Disease.

    McCafferty EH, Scott LJ

    Drugs 2019; (79(5)):543-554 doi:10.1007/s40265-019-01090-4.

    PMID: 30875019
  3. 3

    Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

    Hughes DA, Nicholls K, Shankar SP, et al.

    Journal of medical genetics 2017; (54(4)):288-296 doi:10.1136/jmedgenet-2016-104178.

    PMID: 27834756
  4. 4

    Precision medicine in Fabry disease.

    Lenders M, Brand E

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2021; (36(Suppl 2)):14-23 doi:10.1093/ndt/gfab038.

    PMID: 34153986
  5. 5

    [Chaperone molecules: The example of Fabry disease].

    Barbey F, Monney P, Dormond O

    Nephrologie & therapeutique 2021; (17S()):S11-S22 doi:10.1016/j.nephro.2020.02.005.

    PMID: 33910691
  6. 6

    The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

    Benjamin ER, Della Valle MC, Wu X, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(4)):430-438 doi:10.1038/gim.2016.122.

    PMID: 27657681
  7. 7

    The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.

    Besada P, Gallardo-Gómez M, Pérez-Márquez T, et al.

    Biomolecules 2021; (11(12)) doi:10.3390/biom11121856.

    PMID: 34944500
  8. 8

    Treatment of Anderson-Fabry Disease.

    Simonetta I, Tuttolomondo A, Daidone M, et al.

    Current pharmaceutical design 2020; (26(40)):5089-5099 doi:10.2174/1381612826666200317142412.

    PMID: 32183665
  9. 9

    Strong increase of leukocyte apha-galactosidase A activity in two male patients with Fabry disease following oral chaperone therapy.

    Lamari F, Mauhin W, Koraichi F, et al.

    Molecular genetics & genomic medicine 2019; (7(9)):e894 doi:10.1002/mgg3.894.

    PMID: 31393666
  10. 10

    The migalastat GLP-HEK assay is the gold standard for determining amenability in patients with Fabry disease.

    Schiffmann R, Bichet DG, Benjamin E, et al.

    Molecular genetics and metabolism reports 2019; (20()):100494 doi:10.1016/j.ymgmr.2019.100494.

    PMID: 31367522
  11. 11

    Challenges in Fabry disease: the combination of two individually amenable GLA variants may be nonamenable to migalastat.

    Fernandes RM, Bento D, Marques N, et al.

    Future cardiology 2023; (19(1)):39-43 doi:10.2217/fca-2022-0080.

    PMID: 36695159
  12. 12

    Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year.

    Müntze J, Gensler D, Maniuc O, et al.

    Clinical pharmacology and therapeutics 2019; (105(5)):1224-1233 doi:10.1002/cpt.1321.

    PMID: 30506669
  13. 13

    Migalastat: First Global Approval.

    Markham A

    Drugs 2016; (76(11)):1147-52 doi:10.1007/s40265-016-0607-y.

    PMID: 27351440
  14. 14

    Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis.

    Pisani A, Wilson KM, Batista JL, et al.

    Journal of inherited metabolic disease 2024; (47(5)):1080-1095 doi:10.1002/jimd.12773.

    PMID: 38961737
  15. 15

    Baseline Characteristics of Fabry Disease "Amenable" Migalastat Patients in Argentinian Cohort.

    Jaurretche S, Alonso S, Calvo M, et al.

    Global health, epidemiology and genomics 2024; (2024()):9293896 doi:10.1155/2024/9293896.

    PMID: 38410281
  16. 16

    A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry's Disease.

    Majid H, Verma N, Bhandari S, et al.

    Expert opinion on pharmacotherapy 2024; (25(6)):769-782 doi:10.1080/14656566.2024.2354466.

    PMID: 38753367
  17. 17

    Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?

    Perretta F, Jaurretche S

    Healthcare (Basel, Switzerland) 2023; (11(4)) doi:10.3390/healthcare11040449.

    PMID: 36832983
  18. 18

    Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).

    Lenders M, Nordbeck P, Kurschat C, et al.

    European heart journal. Cardiovascular pharmacotherapy 2022; (8(3)):272-281 doi:10.1093/ehjcvp/pvab025.

    PMID: 35512362
  19. 19

    Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registry.

    Hughes DA, Sunder-Plassmann G, Jovanovic A, et al.

    Journal of inherited metabolic disease 2025; (48(1)):e12771 doi:10.1002/jimd.12771.

    PMID: 39031114
  20. 20

    The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts.

    Chimenti C, Nencini P, Pieruzzi F, et al.

    Orphanet journal of rare diseases 2020; (15(1)):86 doi:10.1186/s13023-020-1318-8.

    PMID: 32264911
  21. 21

    Biochemical Amenability in Fabry Patients Under Chaperone Therapy-How and When to Test?

    Lenders M, Menke ER, Brand E

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2024; (38(6)):845-854 doi:10.1007/s40259-024-00678-x.

    PMID: 39343861
  22. 22

    Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease.

    Lenders M, Nowak A, Cybulla M, et al.

    Orphanet journal of rare diseases 2025; (20(1)):79 doi:10.1186/s13023-025-03600-y.

    PMID: 39980015
  23. 23

    Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.

    Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, et al.

    Molecular genetics and metabolism 2020; (131(1-2)):219-228 doi:10.1016/j.ymgme.2020.07.007.

    PMID: 33012654
  24. 24

    Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study.

    Müntze J, Lau K, Cybulla M, et al.

    Molecular genetics and metabolism 2023; (138(2)):106981 doi:10.1016/j.ymgme.2022.106981.

    PMID: 36709535
  25. 25

    In Vitro and In Vivo Amenability to Migalastat in Fabry Disease.

    Lenders M, Stappers F, Brand E

    Molecular therapy. Methods & clinical development 2020; (19()):24-34 doi:10.1016/j.omtm.2020.08.012.

    PMID: 32995357

This page explains Fabry disease genetics and treatment eligibility for educational purposes. Always consult your medical geneticist or healthcare provider to interpret your specific genetic test results.

Get notified when new evidence is published on Fabry disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.